Royalty Pharma plc Debt Securities, Available-for-sale, Gain (Loss)
Royalty Pharma plc (RPRX) reported Debt Securities, Available-for-sale, Gain (Loss) of $154.91 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleGainLoss · last filed 2025-02-12
- Royalty Pharma plc debt securities, available-for-sale, gain (loss) for fiscal 2024 was $154.91M, a 32.89% decline from fiscal 2023.
- Royalty Pharma plc debt securities, available-for-sale, gain (loss) for fiscal 2023 was $230.84M.
- Royalty Pharma plc debt securities, available-for-sale, gain (loss) for fiscal 2022 was -$6.82M, a 138.16% decline from fiscal 2021.
- Royalty Pharma plc debt securities, available-for-sale, gain (loss) for fiscal 2021 was $17.86M, a 3.98% decline from fiscal 2020.
| Period end | Debt Securities, Available-for-sale, Gain (Loss) 12 month |
|---|---|
| 2024-12-31 | $154.91M 10-K · filed 2025-02-12 |
| 2023-12-31 | $230.84M 10-K · filed 2025-02-12 |
| 2022-12-31 | -$6.82M 10-K · filed 2025-02-12 |
| 2021-12-31 | $17.86M 10-K · filed 2024-02-15 |
| 2020-12-31 | $18.60M 10-K · filed 2023-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |